2022 AGM – Meeting Recording

November 11, 2022May 23, 2023 Alterity Therapeutics

2022

Post navigation

XBRL 30 June 2023 filed with the SEC
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder
Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s
Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

2022 AGM – Meeting Recording

Related Posts

Prana receives $6.8 million R&D Tax Incentive Refund

World leader in movement disorders Professor Ira Shoulson joins Prana board

Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office